SUTENT is used to treat GIST (gastrointestinal stromal tumor). This is a rare cancer of the stomach, bowel, or esophagus. SUTENT is used when the medicine Gleevec® (imatinib mesylate) did not stop the cancer from growing or when you cannot take Gleevec.
Gleevec is a registered trademark of Novartis AG.

To apply for First Resource support, you’ll need an enrollment form. You and your
health care provider must complete it. To get the form, click the link below.
 |
In order to view PDF documents, you must have Adobe® Reader®
installed on your computer. If you do not have Adobe Reader, download it from the
Adobe Web site.
|
Note that the Adobe Web site is neither owned nor controlled by Pfizer. Pfizer is
not responsible for the content or services on that site.
Adobe, the Adobe logo, and Reader are registered trademarks of Adobe Systems Incorporated
in the United States and/or other countries.